Supramolecular dextran, its preparation method and application

Abstract

The application discloses supramolecular dextran as well as a preparation method and application thereof. The supramolecular dextran comprises dextran, betaine and amino acid, the mass ratio of the dextran, the betaine and the amino acid is (1-10):(1-10):(1-10), and the dextran, the betaine and the amino acid form an aggregate structure through non-covalent interaction. The supramolecular dextran is prepared by adding the amino acid into a water solution containing the dextran, stirring once, then adding the betaine, and stirring twice. The obtained supramolecular dextran has excellent moisturizing and barrier repairing effects.

Description

Technical Field

[0001] This invention relates to a supramolecular dextran, its preparation method, and its applications. Background Technology

[0002] The skin's ability to retain moisture reflects the strength of its skin barrier function. Reduced skin hydration leads to a decline in skin barrier function, which in turn further reduces the skin's hydration capacity, creating a vicious cycle. Therefore, skin hydration and repair are key factors in skincare.

[0003] Glucan is a natural polysaccharide composed of D-pyranose glucose units, found in oats, barley, wheat, microorganisms, and fungi. Glucan obtained from grains has its D-pyranose glucose units linked by β-(1-4) and β-(1-3) bonds; while glucans from yeast and fungi are composed of a straight-chain β-(1-3) backbone, although occasionally branched (1-6) chains are also present. Due to its moisturizing, repairing, and soothing properties, it is widely used in the cosmetics industry.

[0004] In the cosmetics industry, betaine and arginine are widely used as small-molecule moisturizers due to their moisturizing properties. Currently, to achieve combined effects, existing technologies typically involve simply physically grinding and mixing multiple active ingredients such as dextran, betaine, and arginine before adding them to cosmetic formulations. However, this simple physical grinding and mixing method has limited synergistic effects between the components; the enhanced efficacy is merely a simple additive effect of each component, which is insufficient to meet the market's demand, especially for individuals with fragile skin barriers such as infants, for gentler and more effective skin moisturizing and barrier repair products. Summary of the Invention

[0005] The technical problem to be solved by this invention is to overcome the shortcomings of existing products containing multiple active ingredients such as glucan, betaine and arginine, which are difficult to effectively exert synergistic effects, and to provide a supramolecular glucan with significantly improved moisturizing and barrier repair effects, as well as its preparation method and application.

[0006] The present invention solves the above-mentioned technical problems through the following technical solution: In a first aspect, the present invention provides a supramolecular dextran, wherein the supramolecular dextran comprises dextran, betaine and amino acids, and the mass ratio of the dextran, betaine and amino acids is (1-10):(1-10):(1-10); Furthermore, the dextran, betaine, and amino acids form aggregate structures through non-covalent interactions.

[0007] In this invention, the term "supramolecular" refers to an ordered aggregate with a specific structure and function formed by two or more molecules through non-covalent intermolecular interactions (such as hydrogen bonds, van der Waals forces, electrostatic interactions, etc.).

[0008] In this invention, "supramolecular dextran" refers to a stable molecular aggregate structure formed through non-covalent interactions, using dextran as the basic framework and compounded with components such as betaine and amino acids. This structure is distinct from molecular aggregates formed by simple physical grinding and mixing of raw materials. Those skilled in the art will understand its specific meaning.

[0009] In this invention, the dextran may be β-glucan; preferably, the β-glucan is selected from one or more of oats, yeast and Schizophyllum commune.

[0010] In this invention, the amino acid can be selected from one or more of arginine, serine, alanine, leucine, glutamic acid, and aspartic acid, with arginine being preferred. Studies have found that, at the same dosage, the degree of self-assembly to form a supramolecular structure is significantly higher when arginine is selected.

[0011] In this invention, the supramolecular dextran may be composed of the dextran, betaine and amino acids, preferably composed of the dextran, betaine and arginine.

[0012] In this invention, the preferred mass ratio of the dextran, betaine, and amino acids is (2-5):(2-5):(2-5), for example, 3:5:2, 3:2:5, 5:2:3, or 5:3:2.

[0013] In some specific embodiments, the supramolecular dextran is composed of dextran, betaine and arginine, and the mass ratio of dextran, betaine and arginine is 3:5:2, 3:2:5, 5:2:3 or 5:3:2, preferably 5:3:2.

[0014] The present invention has found that when the mass ratio of dextran, betaine and arginine is 3:2:5, the most stable structure can be obtained and the synergistic effect of each component can be fully utilized.

[0015] In this invention, with the mass of the dextran as 1 part, the mass of the betaine can be 0.1-10 parts, and the mass of the amino acid can be 0.1-10 parts.

[0016] Preferably, the betaine is present in an amount of 0.4-2.5 parts by mass, for example, 0.6 parts, 0.67 parts or 1.67 parts; and / or, the amino acid is present in an amount of 0.4-2.5 parts by mass, for example, 0.6 parts, 0.67 parts or 1.67 parts.

[0017] In some specific embodiments, the supramolecular dextran is composed of the dextran, betaine, and arginine, wherein the mass of the dextran is 1 part, the mass of the betaine is 1.67 parts, and the mass of the arginine is 0.67 parts. Alternatively, the supramolecular dextran is composed of the dextran, betaine, and arginine, wherein the mass of the dextran is 1 part, the mass of the betaine is 0.67 parts, and the mass of the arginine is 1.67 parts. Alternatively, the supramolecular dextran is composed of the dextran, betaine, and arginine, wherein the mass of the dextran is 1 part, the mass of the betaine is 0.4 parts, and the mass of the arginine is 0.6 parts. Alternatively, the supramolecular dextran is composed of the dextran, betaine, and arginine, with the mass of the dextran being 1 part, the mass of the betaine being 0.6 parts, and the mass of the arginine being 0.4 parts.

[0018] Secondly, the present invention also provides a method for preparing supramolecular dextran, which includes the following steps: Amino acids were added to an aqueous solution containing dextran and stirred once; then betaine was added and stirred a second time to obtain the supramolecular dextran; wherein, The mass ratio of dextran, betaine and amino acids is (1-10):(1-10):(1-10); The temperatures for the primary and secondary stirring are each independently 50-90℃.

[0019] In this invention, the supramolecular dextran, dextran, betaine, and amino acids can be defined as previously.

[0020] In this invention, it has been found that by adding the raw material components (glucan, betaine and amino acids) in the liquid system in the order described above, stirring twice, and coordinating the key parameters (such as temperature) of each stirring, the final self-assembled supramolecular structure (i.e., supramolecular glucan as described above) can be formed.

[0021] In this invention, the relative amounts of the raw material components (dextran, betaine and amino acids) can be used to simultaneously regulate the pH of the final solution. Preferably, the pH is 5.0-9.0.

[0022] In this invention, the terms "first stirring" and "second stirring" are used only to distinguish different stirring steps; that is, both the first stirring and the second stirring involve only a single stirring.

[0023] In this invention, the temperatures of the first stirring and the second stirring are each independently, for example, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C or 85°C.

[0024] In this invention, the rotation speed of the primary and secondary stirring is independently 300-2000 rpm, for example 400 rpm, 500 rpm, 600 rpm, 700 rpm, 800 rpm, 900 rpm, 1000 rpm, 1100 rpm, 1200 rpm, 1300 rpm, 1400 rpm, 1500 rpm, 1600 rpm, 1700 rpm, 1800 rpm, or 1900 rpm.

[0025] In this invention, the time for the first stirring and the second stirring can each be independently 0.5-3h, for example 1h, 1.5h, 2h or 2.5h.

[0026] In this invention, for the primary and secondary stirring, those skilled in the art can reasonably adjust the corresponding stirring time and speed according to the dissolution of each component.

[0027] For example, the endpoint of the first stirring can be the complete dissolution of the amino acid; the endpoint of the second stirring can be the complete dissolution of the betaine, with the viscosity of the resulting solution below 8000 cp, and / or, with the resulting solution being yellow, clear, and transparent overall. Here, "clear and transparent" means that the solution contains no insoluble particles visible to the naked eye, and the solute particle size is less than 1 nm.

[0028] In this invention, the total mass ratio of water in the aqueous solution to the total mass of "the dextran, betaine and amino acids" can be (1-10):(1-10), for example, 1:1.

[0029] In this invention, the secondary stirring step may be followed by a drying step. That is, the final product can exist in solid (anhydrous) form.

[0030] Thirdly, the present invention also provides a supramolecular dextran, which is prepared by the supramolecular dextran preparation method described above.

[0031] Fourthly, the present invention also provides the application of supramolecular dextran as described above in the preparation of products with skin moisturizing and / or skin barrier repair effects.

[0032] In this invention, the skin barrier repair effect may include the upregulation of filaggrin (FLG) and / or lobelin (LOR) expression.

[0033] In this invention, the skin barrier repair effect can be manifested as a reduction in transepidermal water loss rate.

[0034] In this invention, the product may be a cosmetic (such as a skin care product) or a skin preparation.

[0035] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0036] The reagents and raw materials used in this invention are all commercially available.

[0037] The positive and progressive effects of this invention are as follows: This invention utilizes supramolecular technology to form a supramolecular structure that differs from simple physical grinding and mixing compositions by assembling three key components—dextran, betaine, and amino acids—based on non-covalent bonds. This further enhances the moisturizing and repairing properties, and the resulting supramolecular dextran exhibits superior synergistic effects compared to simple physical grinding and mixing compositions. Attached Figure Description

[0038] Figure 1 The Fourier transform infrared spectrum is shown for the supramolecular dextran A (a) and the physically ground mixture A1 (b) in Test Example 1.

[0039] Figure 2 The Fourier transform infrared spectrum is shown for the supramolecular dextran B(a) and the physically ground mixture B1(b) in Test Example 1.

[0040] Figure 3 The Fourier transform infrared spectrum is shown for the supramolecular dextran C(a) and the physically ground mixture C1(b) in Test Example 1.

[0041] Figure 4 The Fourier transform infrared spectrum is shown for the supramolecular dextran D(a) and the physically ground mixture D1(b) in Test Example 1.

[0042] Figure 5 The two-dimensional proton NMR spectrum of supramolecular dextran D in test example 2 is shown.

[0043] Figure 6 This is a comparative data chart showing the water content of the 3D skin model in Test Example 3.

[0044] Figure 7 This is a comparative data graph of transepidermal water loss (TEWL) of the 3D skin model in Test Example 3.

[0045] Figure 8 This is a comparative analysis chart of FLG data for the 3D skin model in Test Example 3.

[0046] Figure 9 This is an FLG fluorescence image of the 3D skin model in Test Example 3.

[0047] Figure 10 This is a comparative analysis chart of LOR data for the 3D skin model in Test Example 3.

[0048] Figure 11 This is a LOR fluorescence photograph of the 3D skin model in Test Example 3. Detailed Implementation

[0049] The present invention will be further illustrated by way of embodiments below, but the present invention is not limited to the scope of the embodiments described herein.

[0050] In this invention, the relevant parameter characterization and effect testing performed on the products obtained in the embodiments and comparative examples, as well as the corresponding methods, are as follows: 1. Infrared testing: The tests were conducted using a Fourier transform infrared spectrometer, model NICOLET is5 (ATR accessory), manufactured by Thermo Fisher Scientific, with 16 scans and a resolution of 4 cm⁻¹. - ¹, Annex ID is 7, wavelength range is 525-4000cm - ¹. In specific testing, simply place the sample to be tested directly on the spectrometer and follow the operating instructions.

[0051] 2. Two-dimensional nuclear magnetic resonance spectroscopy (two-dimensional NOESY test): The measurements were performed using a Bruker 600 MHz nuclear magnetic resonance spectrometer. Tetramethylsilane (TMS) was used as an internal standard, the test temperature was 298 K, and the sample was dissolved in deuterium water. A noesygppr2d pulse sequence with pre-saturated water suppression was used. The relaxation delay time (d1 = 2.0 s) and mixing time (t...) were... m A weak presaturation power is applied during the period (150 ms) to suppress the residual water peak (HOD). The two-dimensional sampling matrix is ​​2048. 256, with each incremental scan performed 16 times. Data is processed using topspin.

[0052] 3. In vitro testing (in vitro cell viability test and 3D skin model verification test): (1) Reagents and equipment The specific information on the reagents and equipment used in this part of the test is shown in Tables 1 and 2 below: Table 1

[0053] Table 2

[0054] (2) Test method

[0055] ① In vitro cell viability test and cell scratch test

[0056] Based on the reagents and instruments listed in Tables 1 and 2, HaCaT cells were first cultured for 24 hours in samples of different concentrations under standard operating conditions. The MTT assay was used to detect the effect of the samples on cell viability, thereby screening out the safe concentration range for each group of samples. After confirming the safe concentration, the cell scratch assay was used to simulate the cell migration microenvironment by creating standardized scratch areas in the central region of the cell monolayer, and the effect of each group of samples on the migration rate of cells in the scratch area was detected.

[0057] ② 3D skin model experiment

[0058] Based on the reagents and instruments listed in Tables 1 and 2, under standard operating conditions in this field, the water content of the 3D skin model was measured in real time using a stratum corneum moisture content analyzer, and the TEWL value was measured in real time using a TEWL analyzer. The results were presented as follows: water content (CU) and TEWL value (g / m³). 2 •h) was used as the evaluation index. In addition, the epidermal model was exposed to the sample and cultured for 24 hours using immunofluorescence method to detect the effect of the sample on the expression levels of FLG and LOR in the epidermal model, and the relative fluorescence intensity (%) was used as the evaluation index.

[0059] The 3D skin model was obtained under standard operating conditions in the field by inoculating and differentiating human primary keratinocytes, resulting in a complete epidermal structure. It was divided into BC, MC, PC, and sample groups. BC refers to the blank group, containing only the original skin model without any drug or test sample treatment. MC refers to the model group, which consists of eczema models obtained through stimulation with PolyI:C (polyinosinic acid-polycytidylic acid) and LPS (lipopolysaccharide). PC refers to the positive control group, which received drug stimulation followed by the addition of dexamethasone. The sample groups received drug stimulation followed by the addition of the test samples from each group. During culture, the BC group was first replaced with fresh culture medium (DMEM basal medium), while the MC, PC, and sample groups were replaced with DMEM basal medium containing PolyI:C and LPS. The skin models were then incubated at 37°C with 5% CO2 for 24 hours. After the culture was completed, the BC group, MC group, PC group and sample group were replaced with fresh culture medium. DEX solution prepared with culture medium was added to the upper chamber of the PC group, and sample solution prepared with culture medium was added to the upper chamber of the sample group. After the culture was completed, relevant indicators were tested.

[0060] In this invention, the specific information of the raw materials used in the following embodiments and comparative examples is shown below: (1) Betaine: purchased from Finnfeeds Finland Oy; (2) Arginine: purchased from Ningbo Zhenhai Haide Biochemical Technology Co., Ltd. / Elephant Co., Ltd.; (3) Glucan: Purchased from Shanghai Zhina Biotechnology Co., Ltd., it is β-glucan, specifically sourced from oats.

[0061] Example 1 Preparation of supramolecular dextran 1

[0062] Weigh the corresponding raw materials according to the raw materials and contents in Table 3, and prepare supramolecular dextran according to the following steps: Add dextran powder to a certain amount of water and stir thoroughly until dissolved to obtain an aqueous solution containing dextran. Add amino acids to the aqueous solution, heat to 50-90℃, and stir once for 0.5-3 hours at a speed of 300-2000 rpm until the amino acids are completely dissolved and the solution is clear and transparent (with no visible insoluble particles). Then, while maintaining the temperature, add betaine and stir a second time for 0.5-3 hours at a speed of 300-2000 rpm until completely dissolved and the solution is yellow, clear, and transparent (with no visible insoluble particles) with a viscosity below 8000 cp. This yields a solution containing supramolecular dextran.

[0063] Table 3

[0064] Comparative Example 1: Preparation of a Physically Milled Mixture

[0065] The only difference between Comparative Example 1 and Example 1 is the preparation method. Specifically, a certain amount of betaine, amino acids, and dextran were weighed according to different mass ratios, and then simply physically ground and mixed (that is, the weighed raw material powders were poured into a mortar and ground directly) to obtain 7 groups of physically ground and mixed compositions. The raw material formulas of the 7 groups of physically ground and mixed compositions are recorded in Table 4.

[0066] The supramolecular dextran samples 1-7 were dried and compared with their corresponding physically ground mixtures. The results showed that the difference between the infrared spectra of sample 1 and its corresponding physically ground mixture was significantly higher than that between the other samples 2-7 and their corresponding physically ground mixtures. Therefore, arginine was used for the preparation of supramolecular dextran in subsequent tests.

[0067] Example 2 Preparation of supramolecular dextran 2

[0068] Weigh out a certain amount of betaine, arginine, and glucan according to different mass ratios.

[0069] Add dextran powder to a certain amount of water and stir thoroughly until dissolved to obtain an aqueous solution containing dextran. Add arginine to the aqueous solution, heat to 50-90℃, and stir once for 0.5-3 hours at a speed of 300-2000 rpm until the amino acids are completely dissolved and the solution is clear and transparent (with no visible insoluble particles). Then, while maintaining the temperature, add betaine and stir a second time for 0.5-3 hours at a speed of 300-2000 rpm until completely dissolved and the solution is yellow, clear, and transparent (with no visible insoluble particles) with a viscosity below 8000 cp. This yields a solution containing supramolecular dextran.

[0070] In this embodiment, four supramolecular dextrans were prepared using the raw material mass ratios recorded in Table 4, and were designated as samples A, B, C, and D, respectively.

[0071] Table 4

[0072] Comparative Example 2: Preparation of Physically Milled Mixtures

[0073] The only difference between Comparative Example 1 and Example 1 is the preparation method. Specifically, a certain amount of betaine, arginine, and dextran were weighed according to different mass ratios, and then simply physically ground and mixed (that is, the weighed raw material powders were poured into a mortar and ground directly) until uniform, resulting in four groups of physically ground and mixed compositions, which were denoted as samples A1, B1, C1, and D1, respectively. The raw material mass ratios of samples A1, B1, C1, and D1 are as recorded in Table 4.

[0074] Table 5

[0075] Test Example 1: Infrared Testing of Supramolecular Dextran Compared to Physically Ground Mixtures

[0076] The supramolecular dextran solutions corresponding to samples A, B, C, and D were heated and dried to remove moisture, resulting in brownish-yellow solid supramolecular dextran. The infrared spectra of these solids were then measured using a Fourier transform infrared spectrometer, along with those of samples A1, B1, C1, and D1.

[0077] For detailed comparison data, please see Figures 1-4 , Figures 1-4 The 'a' part in the diagram corresponds to the results for samples A, B, C, and D, respectively. Figures 1-4 Part b in the figure corresponds to the results of samples A1, B1, C1, and D1, respectively. From the comparison graph, it can be seen that the physically ground mixture in Comparative Example 1 is significantly different from the supramolecular dextran in Example 1. Furthermore, it can be seen from the graph that, with the same mass ratio of the three active ingredients, the differences between samples D and D1 are more pronounced.

[0078] Test Example 2: Nuclear Magnetic Resonance Spectroscopy Test of Supramolecular Dextran Comparative with Physically Ground Mixture

[0079] The supramolecular dextran solution corresponding to sample D was heated and dried to remove the moisture, resulting in a brownish-yellow solid supramolecular dextran. Then, its proton NMR spectrum was tested together with that of betaine, arginine, and dextran alone.

[0080] like Figure 5 As shown in the two-dimensional NMR spectrum, compared with the NMR spectra of betaine, arginine, and dextran alone, it was found that intermolecular hydrogen bonds do exist in sample D, indicating that supramolecular dextran forms a supramolecular structure through intermolecular hydrogen bonds.

[0081] The correlation between (1.5, 3.09) and the hydrogen atom at the 5-methylene position of arginine and the 4-methyl group of dextran indicates a hydrogen bond between the N atom at the 3-position of arginine and the O atom at the 11-position of dextran. Similarly, the correlation between (3.8, 3.1) and the hydrogen atom at the 14-position of betaine indicates a hydrogen bond between the O atom at the 6-position and the hydrogen atom at the 19-position of the hydroxyl group. This demonstrates that dextran, arginine, and betaine form a ternary supramolecular structure through hydrogen bonding.

[0082] Test Example 3: In vitro cell viability test and 3D skin model validation test of supramolecular dextran compared to physically ground mixtures.

[0083] In this test case, the t-test was used for comparisons between groups; "", "", " " indicates a statistically significant difference from group BC, a statistically significant difference, and a highly statistically significant difference, respectively; "#", "##", and "###" indicate a statistically significant difference from group MC, a statistically significant difference, and a highly statistically significant difference, respectively; "+", "++", and "+++" indicate a statistically significant difference between sample groups, a statistically significant difference, and a highly statistically significant difference, respectively. P <0.05 indicates a statistically significant difference. P <0.01 indicates a statistically significant difference. P <0.001 indicates a highly statistically significant difference.

[0084] In addition, the repair effects of samples A, B, C, and D were determined by scratching experiments on keratinocytes at the same concentration of 0.1%. The scratch healing rates were 101.5%, 103.2%, 102.5%, and 108.1%, respectively, indicating that sample D had the best repair effect. Sample D will be selected for further testing.

[0085] Specifically, samples D and D1 were subjected to cytotoxicity and scratch tests on keratinocytes (HaCaT cells), and water content, TEWL, FLG, and LOR were tested on a 3D skin model.

[0086] in: (1) The results of the cell viability assay showed that samples D and D1 had no potential cytotoxicity to HaCaT cells in the test concentration range of 0.04%-0.63%. Based on this result, further experiments were conducted on the HaCaT cell model at a test concentration of 0.2%.

[0087] (2) The results of the cell scratch assay showed that samples D and D1 at a test concentration of 0.2% both promoted the migration of HaCaT cells, with relative increases of 15% and 16%, respectively, and this result was statistically significant. P <0.05), indicating that sample D has a repair efficacy comparable to D1 in this test.

[0088] (3) such as Figure 6 As shown, the water content test results indicate that, in the eczema model, samples D and D1 at a 1% test concentration both increased the water content of the 3D epidermal skin model, with relative increases of 6% and 4%, respectively, and this result was statistically significant. P <0.05). This indicates that sample D has moisturizing effects, and that the moisturizing effect of sample D is better than that of sample D1.

[0089] (4) such as Figure 7 As shown, the TEWL test results indicate that, in the eczema model, samples D and D1 at a 1% test concentration can reduce the TEWL value of the 3D epidermal skin model, with relative inhibition rates of 14% and 9%, respectively, and this result is statistically significant. P <0.05). This indicates that in this test, sample D had a better repair efficacy than sample D1.

[0090] (5) such as Figures 8-11 As shown, the immunofluorescence assay results indicate that, in the eczema model, samples D and D1 at a 1% test concentration increased the FLG fluorescence intensity of the 3D epidermal skin model, with relative increases of 19% and 7%, respectively, and this result was statistically significant. P <0.05); Samples D and D1 at a 1% test concentration increased the LOR fluorescence intensity of the 3D epidermal skin model, with relative increases of 20% and 14%, respectively, and this result was statistically significant. P <0.05). This indicates that sample D has barrier repair efficacy in this test, and that the barrier repair efficacy of sample D is superior to that of sample D1.

[0091] Furthermore, the present invention has found that when comparing samples A and A1, samples B and B1, and samples C and C1, the same differences in performance are observed.

[0092] In summary, the supramolecular dextran obtained in the embodiments of the present invention is significantly superior to the physically ground mixture obtained by simple physical grinding and mixing in the comparative example in terms of moisturizing and repairing effects, and fully exerts the synergistic effect of the three key active substances.

[0093] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and the scope of protection of the present invention is defined by the appended claims. Those skilled in the art can make various changes or modifications to these embodiments without departing from the principles and essence of the present invention, but all such changes and modifications fall within the scope of protection of the present invention.

Claims

1. A supramolecular dextran, characterized in that, The supramolecular dextran comprises dextran, betaine, and amino acids, wherein the mass ratio of dextran, betaine, and amino acids is (1-10):(1-10):(1-10); Furthermore, the dextran, betaine, and amino acids form aggregate structures through non-covalent interactions.

2. The supramolecular dextran as described in claim 1, characterized in that, The supramolecular dextran satisfies one or more of the following conditions: (1) The amino acid is selected from one or more of arginine, serine, alanine, leucine, glutamic acid and aspartic acid; (2) With the mass of the dextran being 1 part, the mass of the betaine is 0.1-10 parts, and the mass of the amino acid is 0.1-10 parts.

3. The supramolecular dextran as described in claim 1, characterized in that, The supramolecular dextran satisfies one or more of the following conditions: (1) The amino acid is arginine; (2) The mass ratio of the dextran, betaine and amino acids is (2-5):(2-5):(2-5); Alternatively, based on 1 part by weight of the dextran, the betaine may be 0.4-2.5 parts by weight; And / or, the mass of the amino acid is 0.4-2.5 parts.

4. The supramolecular dextran as described in claim 1, characterized in that, The supramolecular dextran satisfies one or more of the following conditions: (1) The supramolecular dextran is composed of the dextran, betaine and amino acids; (2) The mass ratio of the dextran, betaine and amino acids is 3:5:2, 3:2:5, 5:2:3 or 5:3:2; Alternatively, based on 1 part by weight of the dextran, the betaine may be 0.6, 0.67, or 1.67 parts by weight; and / or the amino acids may be 0.6, 0.67, or 1.67 parts by weight.

5. The supramolecular dextran according to any one of claims 1-4, characterized in that, The supramolecular dextran satisfies any one of the following conditions: (1) The supramolecular glucan is composed of the glucan, betaine and arginine, and the mass ratio of the glucan, betaine and arginine is 3:5:2, 3:2:5, 5:2:3 or 5:3:2; (2) The supramolecular glucan is composed of the glucan, betaine and arginine, with the mass of the glucan being 1 part, the mass of the betaine being 1.67 parts, and the mass of the arginine being 0.67 parts; (3) The supramolecular glucan is composed of the glucan, betaine and arginine, with the mass of the glucan being 1 part, the mass of the betaine being 0.67 parts, and the mass of the arginine being 1.67 parts; (4) The supramolecular glucan is composed of the glucan, betaine and arginine, with the mass of the glucan being 1 part, the mass of the betaine being 0.4 parts, and the mass of the arginine being 0.6 parts; (5) The supramolecular glucan is composed of the glucan, betaine and arginine, with the mass of the glucan being 1 part, the mass of the betaine being 0.6 parts and the mass of the arginine being 0.4 parts.

6. A method for preparing supramolecular dextran, characterized in that, The preparation method of the supramolecular dextran includes the following steps: Amino acids were added to an aqueous solution containing dextran and stirred once; then betaine was added and stirred a second time to obtain the supramolecular dextran; wherein, The mass ratio of dextran, betaine and amino acids is (1-10):(1-10):(1-10); The temperatures for the primary and secondary stirring are each independently 50-90℃.

7. The method for preparing supramolecular dextran as described in claim 6, characterized in that, The preparation method of the supramolecular dextran satisfies one or more of the following conditions: (1) The amino acid is selected from one or more of arginine, serine, alanine, leucine, glutamic acid and aspartic acid; (2) Based on the mass of the dextran as 1 part, the mass of the betaine is 0.1-10 parts, and the mass of the amino acid is 0.1-10 parts; (3) The temperatures of the first stirring and the second stirring are each independently 55℃, 60℃, 65℃, 70℃, 75℃, 80℃ or 85℃; (4) The rotation speeds of the primary and secondary stirring are each independently 300-2000 rpm; (5) The time for the first and second stirring is 0.5-3h each independently; (6) The ratio of the total mass of water in the aqueous solution to the total mass of "the dextran, betaine and amino acids" is (1-10):(1-10).

8. The method for preparing supramolecular dextran as described in claim 6, characterized in that, The preparation method of the supramolecular dextran satisfies one or more of the following conditions: (1) The amino acid is arginine; (2) The mass ratio of the dextran, betaine and amino acids is (2-5):(2-5):(2-5); Alternatively, based on 1 part by weight of the dextran, the betaine may be 0.4-2.5 parts by weight; And / or, the mass of the amino acid is 0.4-2.5 parts.

9. The use of supramolecular dextran as described in any one of claims 1-5 in the preparation of products having skin moisturizing and / or skin barrier repair effects.

10. The application as described in claim 9, characterized in that, The skin barrier repair effects include upregulation of filaggrin and / or lipogrin expression; And / or, the skin barrier repair effect is manifested as a reduction in transepidermal water loss; And / or, the product is a cosmetic or skin preparation.

Images